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TITLE: 
Type 2 diabetes and glucose intolerance in a population with intellectual disabilities: 
the STOP Diabetes cross-sectional screening study 
 
 
ABSTRACT (284 words)  
Background: 
Adults with intellectual disabilities (ID) may be at increased risk of developing type 2 
diabetes and cardiovascular disease, due to lifestyle factors, medications and other 
diagnosed conditions.  Currently there is lack of evidence on prevalence and 
prevention in this population. The aim of this study was to conduct a diabetes 
screening programme to determine prevalence of previously undiagnosed type 2 
diabetes and impaired glucose regulation in people with ID.  
 
Methods:  
Screening was conducted in a variety of community settings in Leicestershire, UK. 
Adults with ID were invited via: general practices; the Leicestershire Learning 
Disability Register; ID psychiatric services; and some people directly contacted the 
research team due to publicity about the study. Screening involved collection of 
anthropometric, biomedical, and questionnaire data. Type 2 diabetes and impaired 
glucose regulation were defined according to (venous) fasting plasma glucose or 
HbA1c, following current World Health Organisation criteria. 
 
Results: 
930 adults (29% of those approached) participated. Mean age was 43 years, 58% 
were male and 16% of South Asian ethnicity. Most participants were either 
overweight or obese (68%).  Diabetes status was successfully assessed for 675 
(73%) participants: 9 (1.3%, 95% CI 0.6 to 2.5) were found to have undiagnosed 
type 2 diabetes: and 35 (5.2%, 95% CI 3.6 to 7.1) had impaired glucose regulation. 
Key factors associated with abnormal glucose regulation included: non-white 
ethnicity and a first degree family history of diabetes. 
 
Conclusions: 
Results from this large multi-ethnic cohort suggest a low prevalence of screen-
detected (previously undiagnosed) type 2 diabetes and impaired glucose regulation 
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in adults with ID. However, the high levels of overweight and obesity we found 
emphasise the need for targeted lifestyle prevention strategies, which are specifically 
tailored for the needs of people with ID.  
 
 
 
Keywords: 
Type 2 diabetes Impaired glucose regulation Screening  Obesity 
Diabetes  Intellectual Disability  Learning Disability 
 
 
 
 
Headline statements: 
1. First large diabetes screening programme in adults with intellectual disabilities 
 
2. Found low prevalence of screen-detected (previously undiagnosed) diabetes 
in adults with intellectual disabilities 
 
3. High levels of overweight and obesity emphasise need for tailored lifestyle 
prevention strategies for adults with intellectual disabilities   
 
 
 
 
Word count: 4024 (excluding abstract, acknowledgements, reference list, figures, 
tables) 
 
Number of tables: 3  
 
Number of figures: 2  
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BACKGROUND 
People with intellectual disabilities (ID) continue to experience persistent health 
inequalities and higher rates of mortality compared with their non-disabled peers 
(Heslop et al. 2014, Havercamp et al. 2004), and experience barriers in accessing 
healthcare. Hence, early detection of chronic conditions is important, and 
increasingly so for age-related conditions as life expectancy increases (Krahn and 
Fox 2014). 
 
In the general background population, increasing levels of obesity and sedentary 
lifestyles have been associated with a continued rise in non-communicable diseases, 
including type 2 diabetes and cardiovascular disease (World Health Organisation 
2013). For most regions, global prevalence estimates suggest around 9% of the 
adult population have diabetes, with type 2 diabetes accounting for the majority 
(~90%) of cases (International Diabetes Federation 2015, World Health Organisation 
2016). However, a high proportion of people who have type 2 diabetes continue to 
remain undiagnosed (an estimated 39% in Europe, 47% worldwide) and are 
potentially at risk of developing associated health problems (International Diabetes 
Federation 2015). If left untreated or poorly managed, type 2 diabetes can lead to 
serious complications, including heart attacks, stroke, blindness, renal failure, nerve 
damage, amputation and associated mortality, and remains a public health priority 
(International Diabetes Federation 2015). Early identification of type 2 diabetes and 
intervention through screening has been shown to be a useful approach in the 
general adult population (Waugh et al. 2007, Gillies et al. 2008), given the increasing 
prevalence of type 2 diabetes and the conferred risk of developing cardiovascular 
disease. The value of screening for impaired glucose regulation (where blood 
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glucose does not reach the threshold for diabetes but is raised above normal levels) 
has also been demonstrated (Narayan and Gujral 2015).  
 
There are a number of risk factors for type 2 diabetes that are known to be highly 
prevalent in people with ID, suggesting that type 2 diabetes may be more common in 
this group. These include: physical inactivity (Temple et al. 2006); obesity (Krahn 
and Fox 2014, Melville et al. 2007); antipsychotic drug use (for challenging behaviour 
and psychosis) associated with weight gain, hyperglycaemia and other adverse 
metabolic effects (American Diabetes Association et al. 2004); and genetic 
conditions associated with obesity (e.g. Prada-Willi syndrome) (Nagai and Mori 
1999). However, data on the prevalence of type 2 diabetes (both known cases and 
undiagnosed) for people with ID are currently unclear (Emerson et al. 2012). Most 
studies have previously been unable to distinguish between type 2 diabetes and 
other forms of diabetes (McVilly et al. 2014, MacRae et al. 2015). Recent meta-
analytic evidence, derived from a small number of studies (n=5) where type 2 
diabetes has been considered separately from other types of diabetes, suggests an 
overall pooled prevalence of 7.6% (Dunkley 2017). However, this rate includes 
known cases (i.e. those that have already been diagnosed); none of the studies 
focused specifically on screen-detected type 2 diabetes. 
 
People with ID have been recommended as an important group to consider for 
diabetes prevention strategies, given their supposed high risk of developing type 2 
diabetes (NICE 2012, U.S. Department of Health and Human Services 2005). 
However, it is currently unknown whether screening for asymptomatic glucose 
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disorders is viable in populations with ID; there is a lack of evidence on feasibility, 
acceptability, outcomes and benefits. 
 
We conducted a programme of research among people with ID. The STOP Diabetes 
study (Dunkley 2017) consisted of two main components running in parallel: a 
population-based diabetes screening study; and the development of a lifestyle 
education programme. This paper focuses on the screening stage. The primary aims 
of this component were: 1) to develop and assess the feasibility of conducting a 
diabetes screening programme in adults with ID; and 2) to determine the prevalence 
and associated risk factors for screen-detected type 2 diabetes and impaired glucose 
regulation.  
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METHODS 
A cross-sectional population-based diabetes screening study was conducted in a 
community setting, in Leicestershire and Rutland, UK, between December 2012 and 
September 2015.  
 
Participant recruitment 
Potential participants (mild to profound ID, aged 18-74 years) were invited using one 
of four possible approaches: 1) via general practice registers; 2) via the 
Leicestershire Learning Disability Register (Watson 2003, Smith et al. 1996); 3) via 
specialist ID psychiatric service clinics; or 4) people directly contacted the research 
team following study publicity, (see Figure 1). The initial invitation was followed up by 
a telephone call and/or face-to-face visit, to provide further information and conduct a 
preliminary assessment of a person’s decision making capacity. Full study 
information was then provided to eligible volunteers and/or an identified consultee 
(personal/nominated).  Exclusion criteria included: 1) a previous diagnosis of type 1 
or type 2 diabetes; and 2) presence of systemic disease that may interfere with 
measurement and interpretation of glycated haemoglobin (HbA1c, a marker of 
diabetes and longer-term blood glucose).  
[Figure 1 about here] 
Screening process 
Volunteers (and carers) were subsequently invited to attend for screening, usually 
conducted over two appointments (first appointment: consent and data collection; 
second appointment: venepuncture). A trained ID research nurse obtained informed 
consent from the volunteer, or signed approval from the appropriate consultee, in 
line with the English Mental Capacity Act (Department for Constitutional Affairs 
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2007). Data collected included: anthropometric measures (weight, body mass index, 
waist size); blood pressure; bloods (lipids, glucose, HbA1c); and demographic, 
lifestyle and medical history data; For blood tests, the appropriateness of obtaining a 
fasting or non-fasting sample (based on possible behavioural difficulties and/or 
cognition) was discussed in advance with participants (and carers). The most recent 
WHO criteria (World Health Organisation 2011)  were used to define type 2 diabetes 
(HbA1c ≥48 mmol/mol, 6.5%) and impaired glucose regulation (impaired fasting 
glucose (WHO criteria) or HbA1c 42-47 mmol/mol, 6.0-6.4%). Following screening, 
participants (and carers) were informed of their diabetes status; people identified as 
having impaired glucose regulation or type 2 diabetes were referred to their general 
practitioner. Further details of all study data collection procedures and assessment of 
outcomes are described elsewhere. (Dunkley 2017). 
 
Sample size 
Around 4,000 adults with ID were identified as potentially eligible (according to 
estimates provided by the local ID services). We aimed to screen 1,000 adults with 
ID, which would measure the overall prevalence of screen-detected type 2 diabetes 
and impaired glucose regulation with ~1.5% and 2% precision (95% CI) respectively, 
assuming similar prevalence rates of screen-detected type 2 diabetes and impaired 
glucose regulation in people with ID as in the general population (Webb et al. 2011). 
 
Data analysis 
Feasibility of screening was assessed using a flow diagram of the screening process 
and summarising the number of drop outs and those for which data were 
unobtainable at each stage. Particular outcomes of interest in terms of the feasibility 
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were: (i) the proportion of people invited who complete the screening programme 
(including the blood tests); and (ii) the proportion of people who attend the screening 
but do not have a blood test. We also assessed the completeness of other key data 
outcomes to assess the feasibility of data collection for other similar studies.  
 
The characteristics of those screened were summarised using means (standard 
deviations) for continuous variables and n (%) for categorical. The overall prevalence 
of impaired glucose regulation, type 2 diabetes and any abnormal glucose regulation 
(a composite of impaired glucose regulation and type 2 diabetes) were calculated 
with 95% confidence intervals (CI). Logistic regression was used to assess the 
association between key biomedical and anthropometric characteristics and the 
outcome abnormal glucose regulation. Odds Ratios (OR) and 95% CIs were 
calculated.  
 
Cardiovascular risk was calculated for participants aged 35-75 years with no 
previous history of cardiovascular disease. The Framingham risk score (Wilson et al. 
1998, D’Agostino et al. 2008) was used or ETHRISK for people of South Asian origin 
(Brindle et al. 2006). The overall mean risk at 10 years, and level of risk (high, 
intermediate, low) based on thresholds determined by the National Cholesterol 
Education Program (National Cholesterol Education Program Expert Panel 2002), 
were calculated. All analyses were conducted using Stata version 14 (StataCorp.). 
Statistical significance related to p<0.05 and 95% CIs are presented throughout.  
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RESULTS 
Participant recruitment and screening uptake 
A total of 3201 adults with ID were approached to take part in the screening study 
(Figure 1). The majority (n=1736, 54%) were invited via their general practice 
(median per practice, n=19, range 3 to 116). Around 40% were approached via the 
Leicestershire Learning Disability Register (directly invited n=864; previous 
agreement for future research and contact details passed to researchers, n=418). A 
smaller number of people were invited via ID psychiatric clinics (n=52, 2%) or directly 
contacted the research team (n=131, 4%). Forty percent of people responded 
positively to the initial invitation. Following capacity assessment and provision of 
further study information, 984 (31% of those initially invited) proceeded to the 
screening stage (Figure 2).  
[Figure 2 about here] 
Subsequently, at consent, a total of 930 people were recruited into the study, see 
Figure 2; 350 participants (38%) were able to consent for themselves and a 
consultee (personal 23%, nominated 39%) was required for other participants. Key 
screening outcomes were successfully measured for most participants, including 
blood pressure for around 89% and anthropometric measures for around 86%, see 
Table 1. The main documented reasons for not obtaining measurements were 
participant refusal (for blood pressure) and physical or behavioural difficulties (for 
anthropometric measures).  
[Table 1 about here] 
Most participants (n=825) agreed to attend an appointment for a blood test. 
Subsequently, bloods were successfully obtained for 653 (70% of those recruited). 
For five participants, HbA1c results were classed as possibly unreliable and not 
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included in the assessment of diabetes status (due to possible Hb variant, n=1; poor 
kidney function, n=4). For 27 participants where the blood test was refused or 
unsuccessful, an HbA1c test had been taken during the study period as part of their 
routine healthcare (primary/secondary) and this result was obtained from their 
medical records, see Figure 2 and Table 1. Therefore, diabetes status was 
successfully assessed for a total of 675 participants. 
 
Demographic and biomedical characteristics 
The key characteristics of participants are summarised in Table 1. Overall, 58% were 
male, mean age was 43 years (SD 14.2) and 80% were of white ethnicity. Similar 
proportions of participants were classified as having mild, moderate or severe ID 
(~30% each), 4% as profound and for 6% severity of ID was not known. Most 
participants (~70%) had no identified cause of their ID; where known, the most 
common cause was Down’s syndrome (14%). A high proportion of participants 
required 24 hour support (71%) and only 7% reported being independent; most lived 
either with family (36%) or in a residential/nursing home (38%), with 6% living alone.  
 
The majority of participants were classed as either overweight (31%) or obese 
(37%), with mean body mass index (SD 7.1). Mean HbA1c was 35.0 (SD 5.1) 
mmol/mol (5.3%; SD 1.5), fasting plasma glucose 4.7 mmol/l (SD 0.7) and non-
fasting 5.3 mmol/l (SD 1.5). Data reported directly by participants and/or carers 
indicated that only 30% of participants were eating the recommended five or more 
daily portions of fruit, vegetables or salad; most people did at least “some” walking 
on a typical day but only 25% achieved “a lot” of walking; around half reported 
spending “a lot” or “most/all” of the day sitting.  
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The overall prevalence of existing cardiovascular disease was 2% (stroke 1.3%, 
coronary heart disease 0.6%, and one person had both). A history of high cholesterol 
and/or use of lipid lowering medication was reported for 8%, hypertension 
(previously diagnosed and/or currently prescribed an anti-hypertensive) for 9%, and 
4% were prescribed an anti-thrombotic.  A minority of participants were either current 
smokers (8%) or ex-smokers (4%).  
 
Prevalence of type 2 diabetes and impaired glucose regulation 
Of the 675 participants with outcome data to establish prevalence of screen-detected 
impaired glucose regulation/ type 2 diabetes, nine participants (1.3%, 95% CI 0.6 to 
2.5) had previously undiagnosed type 2 diabetes, see Table 2. Thirty-five 
participants (5.2%, 95% CI 3.6 to 7.1) had impaired glucose regulation. Prevalence 
of abnormal glycaemia (combined type 2 diabetes and impaired glucose regulation) 
was 6.5% (95% CI 4.7, 8.4). 
 [Table 2 about here] 
Factors associated with abnormal glucose regulation 
Table 3 shows the association of anthropometric and biomedical characteristics with 
having screen-detected abnormal glycaemia. Participants of non-white ethnicity were 
almost four times more likely to have abnormal glucose levels compared with white 
European participants (OR 3.93; 95% 2.10 to 7.33); those with a first degree family 
history of diabetes were over three times more likely (OR 3.35; 95% 1.64 to 6.86). In 
addition, abnormal glucose levels were associated with increasing weight, BMI, waist 
circumference, hip circumference, diastolic blood pressure and triglycerides, and 
decreasing high density lipoprotein cholesterol.  
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[Table 3 about here] 
Cardiovascular risk 
Cardiovascular risk, was able to be assessed for 376 (40.4%) participants, based on 
Framingham (Wilson et al. 1998, D’Agostino et al. 2008) or ETHRISK (Brindle et al. 
2006). The mean predicted 10-year risk for coronary heart disease was 5.9% (SD 
4.9%) and for cardiovascular disease was 7.3% (SD 6.2%). The majority of 
participants were classed as low (<10%) future risk for coronary heart disease 
(83.5%) and for cardiovascular disease (75.3%). However, 16% of participants were 
classed as high or intermediate risk of developing coronary heart disease in the next 
10 years, and 25% of developing cardiovascular disease. 
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DISCUSSION 
Summary of main findings 
To our knowledge, this is the first large diabetes screening programme conducted in 
adults with ID (who are often classed as a ‘hard-to-reach’ or ‘seldom-heard’ group). 
In total, 930 adults with ID (29% of those approached) participated in the screening 
programme. Most participants were either overweight or obese; 2% had a history of 
existing cardiovascular disease. A high proportion agreed to a blood test and 
subsequently, diabetes status was assessed for 675 participants (73%). The overall 
prevalence of screen-detected (previously undiagnosed) type 2 diabetes was 1.3% 
and impaired glucose regulation 5.2%. Participants of non-white ethnicity (OR 3.93) 
or with a first degree family history of diabetes (OR 3.35) were more likely to have 
abnormal glucose levels. 
  
Comparison with previous evidence 
Data to enable comparison of rates for both screen-detected type 2 diabetes and 
impaired glucose regulation in ID populations are currently limited. We are aware of 
two previous studies (de Winter et al. 2015, Wee et al. 2014) where screening for 
diabetes has been part of the study aim. However, no studies have previously 
included screening for impaired glucose regulation. The Healthy Ageing and 
Intellectual Disability (HA-ID) study (de Winter et al. 2015), which assessed diabetes 
status for a sample of 702 older adults with ID from the Netherlands, found an overall 
prevalence of 12.5% for type 2 diabetes. However, identification of diabetes was 
based on venepuncture (fasting serum glucose level >6.1 mmol/l) and/or current 
medication (use of glucose lowering drugs), and the authors estimate that only 
around half of those identified with diabetes were previously undiagnosed. This is 
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substantially higher than the prevalence (1.3%) that we identified, but may reflect the 
relatively older age of the HA-ID cohort (age ≥50 years, mean 61) in comparison to 
our study (≥18 years, mean 43). A smaller study (n=227) conducted in Singapore 
(Wee et al. 2014) which explored health screening for people with ID and 
cardiovascular risks factors, found an overall prevalence of type 2 diabetes of 10.6% 
but only 3.1% for new screen-detected cases (based on fasting blood glucose). 
Similarly, the population was older than for our study (age ≥40 years, median 46). 
 
Despite finding a lower rate of type 2 diabetes, the high levels of overweight and 
obesity we found (a combined 68%) were broadly the same as those reported by the 
HA-ID study (~64%) and Wee et al (~65%), (de Winter et al. 2012, Wee et al. 2014). 
The proportion of participants who were immobile and/or wheelchair bound across all 
three studies was also very similar (10%, our study; 9% (Wee et al. 2014); 11% (de 
Winter et al. 2015)). 
 
In addition, the low prevalence of abnormal glucose regulation (impaired glucose 
regulation or type 2 diabetes) we found was substantially less than for previous 
diabetes screening studies conducted in non-ID populations, in the same multi-ethnic 
locality. The Let’s Prevent Diabetes and the Walking Away from Diabetes studies 
both identified around 30% of people as having undiagnosed type 2 diabetes or 
impaired glucose regulation (Gray et al. 2012). Although, for these studies, only high 
risk individuals were invited to be screened. 
 
Strengths and limitations 
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The integration of a multi-disciplinary team, consisting of experienced researchers 
and ID healthcare professionals, enabled the successful development and conduct 
of the STOP Diabetes screening programme. This multi-disciplinary approach 
allowed for sharing of knowledge and best practice, and was complemented by 
service user involvement, particularly in the early stages of developing and trialling 
study procedures/processes (Tyrer et al. 2016). 
 
The screening programme developed utilised robust methods. All data were 
collected by staff who had undertaken study specific training and following standard 
operating procedures. Minimal exclusion criteria were applied for including people in 
the study, and ‘reasonable adjustments’ to facilitate inclusion, such as easy-read 
documents, flexible appointments, and carer involvement, maximised participation.  
This ensured that people with all levels of ID (mild to severe/profound) had the 
opportunity to take part and were not arbitrally excluded. Additionally, we applied a 
staged approach to invitation and made efforts to contact/follow-up all people where 
possible.  
 
It is acknowledged that we were unable to establish any contact with approximately 
30% of people, who were non-responders. We therefore do not know if they are 
different in any way to people included in the screening programme; evidence 
suggests that people with mild ID may be at increased risk due to unhealthier 
lifestyles but less likely to access services (Hatton et al. 2014). However, similarities 
in the demographic characteristics of participants in this study (58% male, 20% non-
white ethnicity, 66% aged <50 years), when compared with adults with ID on the 
Leicestershire Learning Disability Register (57% male, 17% non-white ethnicity, 68% 
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<50 years, from data supplied by local ID services), suggests that the STOP 
Diabetes cohort is a representative sample of the ID population known to services 
within the Leicester, Leicestershire and Rutland area. 
 
We recognise that the recruitment approach utilised for the screening study may not 
be transferable to other areas. Recruitment was facilitated by the Leicestershire 
Learning Disability Register, only one of three adult ID case registers in England 
(Watson 2003), and accounted for 40% of people invited (~39% of participants). 
However, we only approached people via this route for general practices that 
declined to take part in the study and we feel that approaches such as direct 
invitation and invitation via ID psychiatric service clinics could possibly be replicated 
in other areas. 
 
A potential limitation of this study is that we were unable to provide an overall 
prevalence rate for type 2 diabetes. Our study specifically aimed to screen adults 
with ID for undiagnosed type 2 diabetes and impaired glucose regulation, using 
similar methodology to previous large studies conducted in the general population 
(Gray et al. 2012). Based on current data for both screen-detected and previously 
diagnosed diabetes supplied at the end of the study by 40 (55%) of the participating 
general practices, the prevalence of diagnosed diabetes (type not specified) locally is 
9.5% (n=148 of 1553 adults 18-74 years with ID), thus inferring a prevalence of 
around 8.5% for type 2 diabetes (based on 85-90% of all diabetes being type 2 (Hex 
et al. 2012)). These rates, alongside the higher recorded uptake of health checks 
conducted annually for people with ID by local general practices (57-66% (Public 
Health England 2014a)) compared with the national average (44%) (Public Health 
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England 2014b), suggest that our findings may simply reflect a successful local 
annual health checks programme. However, it is acknowledged that the proportion of 
adults with ID who currently have bloods checked, including for diabetes, as part of 
their annual health check is unclear. 
 
Implications for clinical practice and future research 
Obesity and sedentary behaviour are both major modifiable risk factors for type 2 
diabetes and cardiovascular disease, and continue to be the focus of diabetes 
prevention initiatives (International Diabetes Federation 2015, World Health 
Organisation 2013). In our study we found high levels of overweight/obesity (68%) 
and sedentary behaviour (around half of participants in our study reported spending 
“a lot” or “most/all” of the day sitting). These findings are in keeping with previously 
reported evidence in the ID population (Hsieh et al. 2014, Stancliffe et al. 2011, 
Melville et al. 2017) and emphasise the need for targeted lifestyle prevention 
strategies which are specifically tailored for the needs of people with ID. 
 
The screening uptake of 29% of those approached was relatively favourable when 
compared with two previous screening/prevention studies conducted locally in the 
general population, where 22% and 19% of those invited took part (Gray et al. 2012). 
Due to the heterogeneity of the ID population and the involvement of carers who 
often act as gate keepers, it may be helpful for future research to explore possible 
reasons for non-participation. Bloods to enable diabetes screening were successfully 
obtained for a high proportion of participants. However, future research may wish to 
consider allowing for separate consent for blood tests so as to not deter people at 
the initial recruitment stage. Very few people directly expressed “the blood test” as a 
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reason for refusal to participate in the screening study; but anecdotal evidence 
suggests this may have deterred some. Alternatively, a staged approach to 
screening, involving risk stratification as recommended by the National Institute for 
Health and Care Excellence in the UK (NICE 2012). This could involve integrating a 
diabetes risk score at practice level to identify high risk people to screen and/or 
development of an accessible risk score for use by carers. 
 
Although the cost effectiveness of screening programmes for impaired glucose 
regulation and diabetes in the general population has been evaluated, we were 
unable to conduct similar work in the ID population owing to the low prevalence of 
screen-detected type 2 diabetes and lack of referral pathways in clinical care.  
 
Conclusion 
In conclusion, results from this large multi-ethnic cohort suggest a low prevalence of 
screen-detected (previously undiagnosed) type 2 diabetes and impaired glucose 
regulation in adults with ID. Studies conducted in the same locality in a non-ID 
population identified 30% with undiagnosed type 2 diabetes or impaired glucose 
regulation. However, the high levels of overweight and obesity we found emphasise 
the need for targeted lifestyle prevention strategies, which are specifically tailored for 
the needs of people with ID.   
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FIGURES AND TABLES 
 
 
 
Figure Legends 
 
 
Figure 1: Recruitment pathway: invitation to screening 
 
 
Figure 2: Flow chart of recruitment 
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Table 1: Key characteristics of participants 
Characteristics     Total no with measure Mean (± SD) or n (%)  
Demographic 
Age (years)      930   43.3 (± 14.2) 
Sex, Male, n (%)     930   537 (57.7) 
Ethnicity, n (%)      930 
White         748 (80.4) 
Asian         147 (15.8) 
Black         14 (1.5) 
Mixed         13 (1.4) 
Other         8 (0.9) 
Severity of ID      865 
Not known         49 (5.7) 
Known         816 (84.3) 
Mild         260 (30.1) 
Moderate        244 (28.2) 
Severe         279 (32.3) 
Profound                     33 (3.8) 
Anthropometric Measurements 
Waist circumference (cm)    796   100.4 (± 16.5) 
Weight ( kg)      799   76.4 (± 20.7) 
BMI (kg/m2)      782   28.7 (± 7.1) 
BMI Categories, n (%)     Underweight       30 (3.8) 
     Normal       223 (28.5) 
     Overweight       241 (30.8) 
     Obese       288 (36.8) 
Blood Pressure Measurements    826 
Systolic (mmHg)        121.4 (± 16.9) 
Diastolic (mmHg)        78.2 (± 11.1) 
Bloods 
Glycated haemoglobin     675 (27) 
HbA1c (mmol/mol)       35.0 (± 5.1) 
Derived HbA1c (%)        5.4 (± 0.5) 
Plasma glucose 
Fasting (mmol/l)     425 (8)   4.7 (± 0.7) 
Non-fasting (mmol/l)    239 (16)  5.3  (± 1.5) 
Lipids 
Total cholesterol (mmol/l)    653   4.9 (± 1.0) 
HDL Cholesterol (mmol/l)    644   1.3 (± 0.4) 
LDL Cholesterol (mmol/l)    631   2.9 (± 0.9) 
Triglycerides (mmol/l) a    407   1.4 (± 0.9) 
Medical history       
Physical Health                                                                  929 
Stroke         13 (1.4) 
Coronary heart disease       7 (0.8) 
Congenital heart disease       19 (2.1) 
Other heart problems       15 (1.6) 
High blood pressure       63 (6.8) 
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High cholesterol        62 (6.7) 
Hypothyroidism        93 (10.0) 
Chronic breathing problems       88 (9.5) 
Epilepsy         262 (28.2) 
Mental Health                                                                   929 
Dementia        18 (1.9) 
Schizophrenia, schizotypal, delusional     35 (3.8) 
Mood (affective) disorders      152 (16.4) 
Neurotic, stress-related, somatoform      143 (15.4) 
Personality disorders       13 (1.4) 
Attention Deficit Hyperactivity Disorder      8 (0.9) 
Autistic spectrum disorders      165 (17.8) 
Behavioural problems       128 (13.8) 
Current medication     928 
Anti-psychotic        240 (25.9) 
Depression / Anxiety/  OCD or related     258 (27.8) 
For ADHD4 (0.4) 
Anti-epileptic        311 (33.5) 
Anti-thrombotic        36 (3.9) 
Lipid lowering        74 (8.0) 
Anti-hypertensive       85 (9.2) 
Thyroid medication       93 (10.0) 
Steroids          80 (8.6) 
Smoking status      929 
Current         76 (8.2) 
Ex         38 (4.1) 
Never         815 (87.7) 
Family history of diabetes    592   180 (30.4) 
Mobility 
Able to walk      927 
Yes (with or without walking stick, aid)     787 (84.9) 
Yes, with assistance from person(s)     83 (9.0) 
No         57 (6.2) 
Amount of walking per day    927 
None         74 (8.0) 
A short distance        259 (27.9) 
Some         359 (38.7) 
Lots         235 (25.4) 
Nutrition and diet 
Problems relating to eating and drinking 
Difficulties with chewing or swallowing  929   227 (24.4) 
Needs help or assistance to feed self  926   118 (12.7) 
Daily portions of fruit and vegetables   920 
5 or more         271 (29.5) 
 a only if fasted.    
Data given as mean (±SD) for continuous outcomes and n (%) for categorical.   
ADHD, Attention deficit hyperactivity disorder; BMI, body mass index; HbA1c, glycated haemoglobin; HDL, high density 
lipoprotein; ID, intellectual disability; LDL, low density lipoprotein; OCD, Obsessive compulsive disorder.  
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Table 2: Prevalence of previously undiagnosed type 2 diabetes and impaired 
glucose regulation 
 
                                                        N (%)  95% CI 
Outcome: 
Normal glucose   631 (93.5)  (91.3, 95.2) 
Impaired glucose regulation 35 (5.2)  (3.6, 7.1) 
Type 2 diabetes   9 (1.3)   (0.6, 2.5) 
Abnormal glucose    44 (6.5)  (4.7, 8.4) 
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Table 3: Comparison of anthropometric and biomedical characteristics of those with 
normal and abnormal glucose regulation  
 
    Normal  Abnormal  OR (95% CI)  P value 
    Glucose Glucose 
    (n = 631) (n=44) 
Age, years   43.0 (±14.3) 45.4 (±13.5) 1.01 (0.99, 1.03) 0.27 
Male    377 (59.8) 28 (63.6) 1.18 (0.63, 2.22) 0.61 
Non-white ethnicity  119 (18.9) 21 (47.7) 3.93 (2.10, 7.33) <0.0001 
Weight, kg   76.6 (±20.2) 91.7 (±27.3) 1.03 (1.01, 1.04) <0.0001 
Waist circumference, cm 100.1 (±16.2) 114.0 (±19.0) 1.04 (1.03, 1.07) <0.0001 
Hip circumference, cm 107.4 (±13.5) 115.6 (±19.1) 1.03 (1.01, 1.06) 0.001 
Body mass index, kg/m2 28.6 (±6.9) 34.1 (±10.2) 1.08 (1.04, 1.13) <0.0001 
Current smoker  56 (8.9) 6 (13.6) 1.62 (0.66, 4.00) 0.30 
FH of diabetes  132 (29.9) 20 (58.8) 3.35 (1.64, 6.86) 0.001 
Systolic BP, mmHg  121.8 (±17.3) 126.5 (±14.4) 1.01 (1.00, 1.03) 0.09 
Diastolic BP, mmHg  78.0 (±11.2) 83.7 (±10.0) 1.04 (1.02, 1.07) 0.002 
Total cholesterol, mmol/l 4.9 (±1.0) 4.7 (±0.9) 0.78 (0.56, 1.10) 0.15 
HDL cholesterol, mmol/l 1.4 (±0.4) 1.2 (±0.3) 0.14 (0.05, 0.43) 0.001 
LDL cholesterol, mmol/l 2.9 (±0.9) 2.7 ±(0.8) 0.71 (0.48, 1.07) 0.10 
Triglycerides, mmol/l 1.4 (±0.9) 1.9 (±1.0) 1.53 (1.11, 2.11) 0.01 
Data given as mean (±SD) for continuous outcomes and n (%) for categorical.  
BP, blood pressure; FH, family history; HDL, high density lipoprotein; LDL, low density lipoprotein. 
 
 


